To the full analysis
Vertex Pharmaceuticals stock: growth
VRTXVertex Pharmaceuticals reported $12.07B in revenue for fiscal 2025, up 9.6% on the prior year, up 14.2% a year on average over up to five years.
Daily figure as of 12 Nov 2026
Revenue (Annual rate)
23.6%
per year from 2006 to 2025, per share 18.4%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 14.2% | 27.9% | 23.6% |
| Revenue per share | 14.6% | 27.1% | 18.4% |
| Earnings | 7.8% | no data | no data |
| Earnings per share | 8.2% | no data | no data |
| Free cash flow | 1.3% | no data | no data |
| Free cash flow per share | 1.6% | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $216.36M | −$206.89M | −$54.89M |
| 2007 | $199.01M | −$391.28M | −$284.89M |
| 2008 | $175.5M | −$459.85M | −$258.66M |
| 2009 | $102.05M | −$641.58M | −$451.08M |
| 2010 | $143.37M | −$754.63M | −$673.5M |
| 2011 | $1.41B | $29.57M | $49.14M |
| 2012 | $1.53B | −$107.03M | $196.7M |
| 2013 | $1.21B | −$445.03M | −$102.96M |
| 2014 | $580.42M | −$738.56M | −$564.4M |
| 2015 | $1.03B | −$558.12M | −$410.73M |
| 2016 | $1.7B | −$112.05M | $179.54M |
| 2017 | $2.49B | $263.48M | $585.52M |
| 2018 | $3.05B | $2.1B | $1.17B |
| 2019 | $4.16B | $1.18B | $1.49B |
| 2020 | $6.21B | $2.71B | $2.99B |
| 2021 | $7.57B | $2.34B | $2.41B |
| 2022 | $8.93B | $3.32B | $3.93B |
| 2023 | $9.87B | $3.62B | $3.28B |
| 2024 | $11.02B | −$535.6M | −$790.3M |
| 2025 | $12.07B | $3.95B | $3.19B |
Revenue by segment
How Vertex Pharmaceuticals Incorporated makes its money and how that has shifted. Names are as the company reports them.
- Trikafta/Kaftrio$10.3B85%
- Alyftrek$837.8M7%
- Manufactured Product, Other$820.1M7%
The company split earlier years differently. A history would not be comparable, so only 2025 is shown.
Figures as a table
| 2025 | Share 2025 | |
|---|---|---|
| Trikafta/Kaftrio | $10.31B | 85.4% |
| Alyftrek | $837.8M | 6.9% |
| Manufactured Product, Other | $820.1M | 6.8% |
| Total revenue | $12.07B | 100% |
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 8 May 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.